[Helicobacter pylori and the treatment of gastric ulcer. Reflections and uncertainties].
The authors examine the relationship between Helicobacter pylori and gastric ulcer therapy, analyzing both the data suggesting that eradication of the organism renders the gastric mucosa less susceptible to development of gastric ulcer and the substantial body of evidence to the contrary. They review the results reported in clinical trials with colloidal bismuth subcitrate, antimicrobial agents (furazolidone), and combinations of antiulcer and antimicrobial agents (H2-antagonist + cefixime, H2-antagonist + metronidazole). Also analyzed is the relationship between Helicobacter pylori eradication and ulcer recurrence; only one study is available on this aspect, and the limited evidence it provides in favour of a prophylactic effect of eradication therapy is not entirely convincing. The authors conclude that there is no reasonable case for the dogmatic assumption that eradication of Helicobacter pylori facilitates either acute healing or long-term prophylaxis of gastric ulcer, though certain subgroups of gastric ulcer patients may benefit from eradication therapy.
Dobrilla
G
G
División de Gastroenterología, Hospital General Regional, Bolzano, Italia.
Piazzi
L
L
Amplatz
S
S
D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology
D000897:Anti-Ulcer Agents; D005664:Furazolidone